$NLTX News
Last published 2y ago
- 2y agoNLTXNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitGlobeNewswireSEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated
- 3y agoNLTXNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitGlobeNewswireSEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated
- 3y agoAMNBNLTXPRDSSCUMoore Kuehn Encourages PRDS, AMNB, NLTX, and SCU Investors to Contact Law FirmPR NewswireNEW YORK, Aug. 3, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoAMNBNLTXPRDSSCUMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmGlobeNewswireNEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoNLTXNeurogene and Neoleukin Announce Definitive Merger AgreementGlobeNewswireProposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene's differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected to have a cash
- 3y agoNLTXNeoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionGlobeNewswireSEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics,
- 3y agoNLTXNeoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual MeetingGlobeNewswireSEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics,
- 3y agoNLTXNeoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate UpdateGlobeNewswire-- Development of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into the second half of
- 4y agoNLTXNeoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual MeetingGlobeNewswireSEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics,
- 4y agoNLTXNeoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate UpdateGlobeNewswireSEATTLE, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for
- 4y agoNLTXNeoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth ConferenceGlobeNewswireSEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachm
- 4y agoNLTXNeoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022GlobeNewswireSEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a con
- 4y agoNLTXNeoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)GlobeNewswireSEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of the firs
- 4y agoNLTXNeoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate UpdateGlobeNewswireSEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for t
- 4y agoNLTXNeoleukin Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachma
- 4y agoNLTXNeoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual MeetingGlobeNewswire- NL-201 demonstrates antitumor activity in preclinical B-cell lymphoma models - - NL-201 synergizes with radiation therapy to generate potent, antitumor immunity - SEATTLE, April 13, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc.,
- 4y agoNLTXNeoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology ConferenceGlobeNewswireSEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drach
- 4y agoNLTXNeoleukin Therapeutics Announces Appointment of Donna Cochener as General CounselGlobeNewswireSEATTLE, March 15, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of
- 4y agoNLTXNeoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireSEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three presentations
- 4y agoETNBNLTXNeoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate UpdateGlobeNewswire- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - A
- 4y agoNLTXNeoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022GlobeNewswireSEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced , today announced it
- 4y agoNLTXNeoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology ConferenceGlobeNewswireSEATTLE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachm
- 4y agoNLTXNeoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)GlobeNewswire- NL-201 plus pembrolizumab to be evaluated in advanced solid tumor patients -- Combination testing anticipated to begin in 2022 - SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceuti
- 4y agoNLTXNeoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual ConferenceGlobeNewswireSEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachm
- 4y agoNLTXNeoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)GlobeNewswire– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma model – SEATTLE, Dec. 11, 2021 (GL
- 5y agoNLTXNeoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)GlobeNewswireSEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of
- 5y agoNLTXNeoleukin Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will
- 5y agoNLTXNeoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate UpdateGlobeNewswire– NL-201 Phase 1 solid tumor trial interim data anticipated in 2022 – – Upcoming presentations at ACR, SITC, and ASH to highlight preclinical data – – Planning to initiate a Phase 1 trial in hematologic malignancies with NL-201 in
- 5y agoNLTXNeoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)GlobeNewswireSEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of fo
- 5y agoNLTXNeoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of ConcernGlobeNewswire– Single intranasal dose of NL-CVX1 in mice prevents infection by multiple variants of SARS-CoV-2 – – Transgenic mice that are protected from disease by NL-CVX1 remain resistant to rechallenge after one month – SEATTLE, Sept. 29, 2021
- 5y agoNLTXNeoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of ResearchGlobeNewswireSEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of
- 5y agoNLTXNeoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate UpdateGlobeNewswireSEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for
- 5y agoNLTXNeoleukin Therapeutics to Participate in Jefferies Virtual Healthcare ConferenceGlobeNewswireSEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachma
- 5y agoNLTXNeoleukin Therapeutics Announces Initiation of Phase 1 NL-201 TrialGlobeNewswireSEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced dosing the first pati
- 5y agoNLTXNeoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare ConferenceGlobeNewswireSEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachma
- 5y agoNLTXNeoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical OfficerGlobeNewswireSEATTLE, May 03, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Pr
- 5y agoNLTXNeoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United StatesGlobeNewswireSEATTLE, April 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that the U.S. Food
- 5y agoNLTXNeoleukin Therapeutics, Inc. (NLTX) Q4 2020 Earnings Call TranscriptEarnings Call TranscriptsNLTX earnings call for the period ending December 31, 2020.
- 5y agoNLTXNeoleukin Therapeutics Announces Year End 2020 Financial ResultsGlobeNewswire- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 - - Cash and cash equivalents of $192.6 million expected to fund operations into 2023 - - Company to host Conference Call Today,...
- 5y agoNLTXNeoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021GlobeNewswireSEATTLE, March 18, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
- 5y agoNLTXNeoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences ConferenceGlobeNewswireSEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
- 5y agoNLTXNeoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology DaysGlobeNewswireSEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
- 5y agoNLTXNeoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201GlobeNewswireSEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
- 5y agoNLTXNeoleukin Therapeutics to Present at J.P. Morgan Healthcare ConferenceGlobeNewswireSEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
- 5y agoNLTXNeoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for CancerGlobeNewswireSEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
- 5y agoNLTXNeoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewswireSEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
- 6y agoNLTXNeoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceGlobeNewswireSEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
- 6y agoNLTXNeoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)GlobeNewswire- NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation - SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics,...
- 6y agoNLTXNeoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate UpdateGlobeNewswire-NL-201 IND submission anticipated by year end 2020- -Clinical Trial Notification application submitted in Australia- -Ended 3rd quarter with $201.2 million in cash and cash equivalents- ...
- 6y agoNLTXNeoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In VivoGlobeNewswire- Intranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection – - Designed to resist viral mutational escape by mimicking the natural target of the spike protein - ...